Loading
MT-304 is an experimental in vivo CAR therapy from CREATE Medicines, in phase 1 trials for solid tumours that carry HER2.
MT-304 is an in vivo CAR therapy: mRNA in lipid nanoparticles that programmes NK and myeloid cells from CREATE Medicines. Messenger RNA in lipid nanoparticles makes the patient's own NK cells and myeloid cells carry a chimeric antigen receptor against HER2. The phase 1 study NCT07334119 tests it alone and with nivolumab in HER2-expressing solid tumours. Whether it works in people has not been established.
Messenger RNA in lipid nanoparticles makes the patient's own NK cells and myeloid cells carry a chimeric antigen receptor against HER2. Connects to HER2.
1.MT-304 slips into a pocket on HER2.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MT-304" OR ABSTRACT:"MT-304") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MT-304, not a curated reading list.
Shares CREATE Medicines and the tag pipeline.
Shares CREATE Medicines and the tag pipeline.
Shares HER2 and the tag pipeline.
Shares HER2 and the tag pipeline.
Shares HER2 and the tag pipeline.
Shares HER2 and the tag pipeline.
Shares HER2 and the tag pipeline.
Shares HER2 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/